Abstract 296P
Background
Despite the knowledge that HPV is responsible for high-grade CIN and cervical cancer, little is known about the use of therapeutic vaccines as treatment considering most studies are still in early stages. We aimed to synthesize and critically evaluate the evidence from clinical trials on the safety, efficacy, and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade CIN associated with HPV.
Methods
A systematic review of clinical trials adhering to the PRISMA 2020 statement was undertaken in MEDLINE/PubMed, Embase, CENTRAL Cochrane, Web-of-Science, Scopus, and LILACS, with no data or language restriction. Primary endpoint related to the safety, efficacy, and immunogenicity of these vaccines were assessed by analyzing the adverse/toxic effects associated with the therapeutic vaccine administration; via histopathological regression of the lesion and/or regression of the lesion size and by viral clearance; and through the immunological response of individuals who received treatment compared to those who did not or before and after receiving the vaccine, respectively.
Results
A total of 1,184 studies were identified, and 16 met all criteria. Overall, the therapeutic vaccines were heterogeneous regarding their formulation, dose, intervention protocol and routes of administration making meta-analysis unfeasible. In most studies (n=15), the vaccines were safe and well tolerated, with clinical efficacy with regards to lesions and histopathological regression or viral clearance. In addition, 11 studies showed favorable immunological responses against HPV, and seven studies showed a positive correlation between immunogenicity and clinical response, indicating promising results that should be further investigated.
Conclusions
Therapeutic vaccines, although urgently needed for avoid progression of CIN 2/3 patients, still present sparse data, requiring greater investments in well-designed phase III RCT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract